Original scientific paper

Thrombolysis for Acute Ischemic Stroke - Our Experiences as Part of SITS-MOST

Marina Roje-Bedeković
Vesna Vargek-Solter
Lejla Čorić
Karla Sabolek
Tomislav Breitenfeld
Višnja Supanc
Vida Demarin

Abstract

Thrombolysis with intravenous recombinant tissue plasminogen activator (rt-PA) is the first evidence based treatment for acute ischemic stroke, which aims to reduce the cerebrovascular lesion. At University Department of Neurology, Sestre milosrdnice University Hospital, Zagreb, thrombolytic therapy with intravenous rt-PA (alteplase) (Actrlyse®) for acute ischemic stroke was introduced in 2004. We present our results referring to demographic, time logistics and clinical outcome data as part of SITS-MOST (Safe Implementation of Thrombolysis in Stroke - MOnitoring STudy) and compare them with the results from other centers in Croatia and all other participating centers. Up to now, 56patients (61% of male and 39% of female, average age 67 years) have been treated at our department with intravenous rt-PA (0.9 mg/kg body weight, maximum 90 mg), with 10% of the dose given asabolus followed by 60-minute infusion. Our experiences with thrombolytic therapy with intravenous rt-PA (alteplase) (Aculyse®) for acute ischemic stroke confirm the safety and the efficacy of this therapy.

Keywords

Brain ischemia - drug therapy; Stroke - drug therapy; Thrombolytic therapy; Fibrinolytic agents - therapeutic use

Hrčak ID:

45145

URI

https://hrcak.srce.hr/45145

Publication date:

1.9.2009.

Article data in other languages: croatian

Visits: 5.816 *